Share

Profile & Fundamentals

PROCEPT BioRobotics Profile & Fundamentals

Name: PROCEPT BioRobotics financial chart data preview
Creator: iPulse AI
License: https://ipulseai.com/terms

Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.

Interactive annual & quarterly chartsAI financial reviewsReported source tables

Explore this pageJump to a Profile & Fundamentals section

Explore this research

Profile & Fundamentals contents

Jump directly to any section

Company and Market Context

Company Profile & Ownership

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

Company profile record

Procept Biorobotics Corp

Common Stock · Health Care · Health Care Equipment

Official website

Company

Company / asset: Procept Biorobotics Corp
Security type: Common Stock
Sector: Health Care
Industry: Health Care Equipment
HQ: 🇺🇸 United States
Head office: 150 Baytech Drive, San Jose, CA, United States, 95134

Leadership & scale

Chief executive: Mr. Larry L. Wood
CEO year born: 1966
Full-time employees: 888
Fiscal year end: December
IPO date: 2021-09-15

Fundamentals snapshot

Updated 2026-09-16

Market Cap: USD 1.1B
P/E: --
Revenue (Q2 26): USD 94.5M
Profit (Q2 26): USD -26.9M
Dividend Yield: --
Revenue (FY 25): USD 308.1M
Shares in public float: 55.8M
Insider ownership: 3.28%

Reporting & identifiers

Symbol: PRCT.NASDAQ
Listing: 🇺🇸 United States | Dividend Tax: 30%
Ticker Currency: USD
Income Statement Currency: USD
Balance Sheet Currency: USD
Cash Flow Currency: USD
EPS Currency: USD
Contract Type: SPOT
ISIN: US74276L1052
Asset ID: equity_e65c5513-7215-53aa-b62b-82394d2ae179

Ownership

Shares Outstanding

Shares outstanding

Annual reported shares outstanding. Values in shares.

Top holders

BlackRock Inc4,362,002 shares · 7.62% · Reported 2026-03-31
T. Rowe Price Investment Management,Inc.3,273,794 shares · 5.72% · Reported 2026-03-31
BNP Paribas Investment Partners SA3,089,378 shares · 5.39% · Reported 2026-03-31
Vanguard Portfolio Management, LLC2,421,362 shares · 4.23% · Reported 2026-03-31
Vanguard Capital Management, LLC2,399,067 shares · 4.19% · Reported 2026-03-31
Chicago Capital LLC2,073,237 shares · 3.62% · Reported 2026-06-30
Mackenzie Investments1,720,738 shares · 3.00% · Reported 2026-03-31

View more holders (8)

Vanguard MStar Total Stk Mkt Idx Invest1,708,164 shares · 2.98% · Reported 2026-07-31
State Street Corp1,529,631 shares · 2.67% · Reported 2026-03-31
FMR Inc1,461,904 shares · 2.55% · Reported 2026-03-31
iShares Russell 2000 ETF1,436,778 shares · 2.51% · Reported 2026-08-31
Geode Capital Management, LLC1,363,500 shares · 2.38% · Reported 2026-03-31
T. Rowe Price US Small-Cap Core Equity1,318,120 shares · 2.30% · Reported 2026-06-30
T. Rowe Price Small-Cap Stock1,317,040 shares · 2.30% · Reported 2026-07-31
Wellington Management Company LLP1,274,004 shares · 2.22% · Reported 2026-06-30

Earnings, Profitability & Valuation

Earnings & Revenue

Revenue, Net Income, and Free Cash Flow

Revenue
Free cash flow
Net income

Annual reported financial results, converted using the statement's recorded USD conversion. Missing values are omitted. Values in USD.

Valuation

Historical P/E Ratio

The published data is insufficient to draw this chart.

Profitability & Margins

AI Review

Gross profit margins tell a positive operational story, climbing from 52.2% in 2023 to 63.7% in 2025 and reaching 66% in mid-2026. This steady expansion reflects strong pricing for single-use surgical handpieces at $3,550 and higher selling prices for next-generation robotic consoles, although a $2.9 million tariff refund provided temporary support. In contrast, operating profit margins remain deeply negative at roughly minus 29% due to extensive sales teams and clinical trial spending. As recurring, high-margin handpiece sales become a larger share of total revenue, fixed corporate overhead will be spread over more cases, paving the way for operating profits as annual surgeries continue to scale.

Profitability Margins

Gross margin
Operating margin
Net margin
Free cash flow margin

Annual gross, operating, net income and free cash flow divided by revenue for matching reporting dates. Values in percent.

Complete Research Workspace

Unlock the complete Profile & Fundamentals

Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.

Sign in to check access View Base plan

Paywalled preview begins: Reported Data Tables — chart preview

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Reported Data Tables — chart preview

The following tables contain the same values as the financial charts above. Monetary values are USD; margins are percentages. Missing inputs are not estimated. Use is subject to the iPulse AI Terms of Service and applicable source rights.

Source: eodhd. Statement snapshots with chart transformations and ratios calculated by iPulse AI. Snapshot retrieved 2026-09-17.

Annual earnings and profitability
Period end	Revenue	Free cash flow	Net income	Gross margin	Operating margin	Net margin	Free cash flow margin
2019-12-31	6,169,000	-51,429,000	-41,975,000	-30.56	-705.95	-680.42	-833.67
2020-12-31	7,717,000	-48,576,000	-53,019,000	-16.26	-619.44	-687.04	-629.47
2021-12-31	34,473,000	-57,926,000	-59,853,000	46.02	-157.12	-173.62	-168.03
2022-12-31	75,014,000	-83,035,000	-87,154,000	49.44	-107.61	-116.18	-110.69
2023-12-31	136,191,000	-133,209,000	-105,897,000	52.17	-80.16	-77.76	-97.81
2024-12-31	224,498,000	-103,622,000	-91,413,000	61.07	-43.04	-40.72	-46.16
2025-12-31	308,054,000	-58,341,000	-95,572,000	63.7	-33.71	-31.02	-18.94

Shares outstanding — chart values
Reporting date	Shares outstanding
2020-01-01	35,138,000
2021-01-01	43,540,000
2022-01-01	44,770,000
2023-01-01	50,589,000
2024-01-01	53,838,000
2025-01-01	56,071,000
2026-01-01	56,511,000

End of the paywalled preview

The excerpt from Reported Data Tables — chart preview to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

Earnings, Profitability & Valuation
- Complete profitability ratios
- EPS history and estimate comparisons
- Execution vs expectations
- Annual and quarterly financial views
Capital Expenditure & R&D
- Capital allocation AI review
- Annual capital expenditure
- Investment intensity trends
- Capex and R&D intensity indicators
Balance Sheet
- Balance sheet AI review
- Assets, debt and equity
- Capital structure
- Liquidity and leverage
- Retained earnings
Dividends & Actions
- Cash dividends paid
- Dividend indicators
- Buybacks and issuance
- Combined shareholder returns
- Available corporate actions
Company Events
- Dated insider transactions
- Material company activity

Explore complete public research examples

These public assets show the complete asset profiles, fundamental datasets and analysis. Their findings concern those assets, not this report.